Machine Learning Analysis of the Orbitofrontal Cortex Transcriptome of Human Opioid Users Identifies Shisa7 as a Translational Target Relevant for Heroin Seeking Leveraging a Male Rat Model.

Journal: Biological psychiatry
Published Date:

Abstract

BACKGROUND: Identifying neurobiological targets predictive of the molecular neuropathophysiological signature of human opioid use disorder (OUD) could expedite new treatments. OUD is characterized by dysregulated cognition and goal-directed behavior mediated by the orbitofrontal cortex (OFC), and next-generation sequencing could provide insights regarding novel targets.

Authors

  • Randall J Ellis
    Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Psychiatry, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Addiction Institute of Mount Sinai, New York, New York.
  • Jacqueline-Marie N Ferland
    Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Psychiatry, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Addiction Institute of Mount Sinai, New York, New York.
  • Tanni Rahman
    Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Joseph L Landry
    Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Psychiatry, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Addiction Institute of Mount Sinai, New York, New York.
  • James E Callens
    Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Psychiatry, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Gaurav Pandey
    Icahn Institute for Genomics and Multiscale Biology and Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: gaurav.pandey@mssm.edu.
  • TuKiet Lam
    Keck Mass Spectrometry and Proteomics Resource, WM Keck Foundation Biotechnology Resource Laboratory, Yale School of Medicine, New Haven, Connecticut; Department of Biophysics and Biochemistry, Yale University, New Haven, Connecticut.
  • Jean Kanyo
    Keck Mass Spectrometry and Proteomics Resource, WM Keck Foundation Biotechnology Resource Laboratory, Yale School of Medicine, New Haven, Connecticut.
  • Angus C Nairn
    Yale Department of Psychiatry, New Haven, CT, USA.
  • Stella Dracheva
    Department of Psychiatry, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Research and Development, James J. Peters VA Medical Center, Bronx, New York.
  • Yasmin L Hurd
    Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Psychiatry, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Addiction Institute of Mount Sinai, New York, New York. Electronic address: yasmin.hurd@mssm.edu.